Abstract
Background: We previously demonstrated that isovitexin (apigenin-6-C-glucoside, ISOV) suppressed the stemness of human Hepatocellular Carcinoma (HCC) cells. However, the mechanism of its action remains to be deciphered.
Objective: The current study was to examine whether ISOV regulates the miR-34a expression and hence suppresses the stemness of HCC SK-Hep-1 cells.
Methods: After identification of the stemness, apoptosis resistance and decreased miR-34a expression of spheres from SK-Hep-1 cells (SK-SC), we utilized transfection of a miR-34a mimic or inhibitor to investigate the effects of ISOV on miR-34a, Bcl-2, Bax and Mcl-1 expression in order to understand the mechanism underlying ISOV-mediated repression of stemness and promotion of apoptosis.
Results: Our results demonstrated that SK-SC displayed higher stemness and resistance to apoptosis, as well as reduced miR-34a levels compared to SK-Hep-1 cells. ISOV suppressed sphere and colony formation, and decreased CD44+ cell populations. In addition, ABCG2, ALDH1, and NANOG mRNA levels were decreased, while there was a concomitant increase in miR-34a levels. With regards to apoptosis-related proteins, ISOV increased Bax protein levels, and reduced Bcl-2 and Mcl-1 protein levels in SK-SC. Importantly, there was a cooperative effect when miR-34a was overexpressed in the presence of ISOV in SK-SC, and down-regulation of miR-34a attenuated the effects of ISOV in SK-Hep-1 cells.
Conclusion: We suggest that ISOV-mediated miR-34a upregulation induces apoptosis and suppresses the stemness of SK-SC. Our data indicate that ISOV exhibits therapeutic potential for the treatment of HCC.
Keywords: Hepatocellular carcinoma, cancer stem cell, isovitexin, miR-34a, apoptosis, Bcl-2, Mcl-1, Bax.
Graphical Abstract
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[http://dx.doi.org/10.1172/JCI66024] [PMID: 23635789]
[http://dx.doi.org/10.3390/biomedicines5040065] [PMID: 29156578]
[http://dx.doi.org/10.3390/biom9070257] [PMID: 31277238]
[http://dx.doi.org/10.5001/omj.2019.43] [PMID: 31110630]
[http://dx.doi.org/10.1590/1678-9199-jvatitd-2019-0010] [PMID: 31384244]
[http://dx.doi.org/10.1016/j.phrs.2017.11.027] [PMID: 29197639]
[http://dx.doi.org/10.1111/nyas.13446] [PMID: 28891090]
[http://dx.doi.org/10.1016/j.sjbs.2014.02.002] [PMID: 25473363]
[http://dx.doi.org/10.1016/j.fitote.2016.09.011] [PMID: 27693342]
[http://dx.doi.org/10.1016/j.phymed.2010.04.005] [PMID: 20576412]
[http://dx.doi.org/10.3389/fphar.2017.00895] [PMID: 29326585]
[http://dx.doi.org/10.1016/j.bbrc.2018.01.111] [PMID: 29355527]
[http://dx.doi.org/10.1186/s13046-019-1244-6] [PMID: 31208440]
[http://dx.doi.org/10.1158/0008-5472.CAN-17-1915] [PMID: 28947421]
[http://dx.doi.org/10.3390/jcm4111951] [PMID: 26580663]
[http://dx.doi.org/10.18632/oncotarget.3394] [PMID: 25826085]
[http://dx.doi.org/10.3892/ol.2018.9427] [PMID: 30405796]
[http://dx.doi.org/10.2147/OTT.S142446] [PMID: 29062236]
[http://dx.doi.org/10.1155/2014/258695] [PMID: 24829923]
[http://dx.doi.org/10.1002/mgg3.469] [PMID: 30221494]
[http://dx.doi.org/10.1186/1471-2407-14-722] [PMID: 25260650]
[PMID: 20878083]
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0391] [PMID: 27765853]
[http://dx.doi.org/10.1111/cas.13527] [PMID: 29417690]
[http://dx.doi.org/10.3748/wjg.v25.i22.2752] [PMID: 31235998]
[http://dx.doi.org/10.2147/CMAR.S202664] [PMID: 31114344]
[PMID: 28123637]
[http://dx.doi.org/10.4103/0973-1482.148673] [PMID: 27072269]
[http://dx.doi.org/10.1371/journal.pone.0024099] [PMID: 21909380]
[http://dx.doi.org/10.1371/journal.pone.0051306] [PMID: 23251493]
[http://dx.doi.org/10.2174/1871520618666180315090949] [PMID: 29542423]